ASSESSMENT OF IRON METABOLISM DISORDERS AND ADEQUATE TREATMENT OF ANEMIC SYNDROME IN PATIENTS WITH BREAST CANCER ON THE BACKGROUND OF ADJUVANT CHEMOTHERAPY
Early and adequate correction of the anemic syndrome (AS) of cancer patients can prevent deterioration in the quality of life and be considered as a reserve for increasing the effectiveness of treatment for breast cancer (BC). The aim of the study was to assess the status of iron using modern methods of ferrokinetics in breast cancer patients on the background of adjuvant chemotherapy for early diagnosis and adequate treatment of AS. The object of the study included 21 breast cancer patients with a relatively favorable prognosis, with luminal types A and B (Her 2 / neu positive or negative), three times negative type. The examination was carried out in the postoperative period, against the background of adjuvant chemotherapy. The main metabolites of ferrokinetics were studied: hepcidin 25 (GP25); ferritin (FR); soluble transferrin receptors (rRTP); transferin (TRF); iron (Fe); erythropoietin (EPO); CRP and IL-6 indicators. AC correction was performed (ferinject, epotin-alpha, B12). 10 (47.6%) patients with breast cancer had AS. Most of them were diagnosed with IDA with microcytic, hypochromic characteristics of erythrocytes, low concentration of FR, Fe, GP25, IL-6, CRP, and high levels of TRP and rRTP. Functional iron deficiency (FDF) was established in some patients. In contrast to patients with IDA, they had a high concentration of FR, CRP and significant production of GP25, IL-6. The EPO level was not optimal for the majority of patients with AS. In isolated cases, during treatment with recombinant erythropoietins, a deficiency of vitamin B12 (cyanocobalamin) was revealed. The rational use of iron preparations, vitamins, and recombinant forms of EPO made it possible to restore Fe metabolism, stabilize the hemoglobin level, and also improve the condition of most breast cancer patients. The obtained data on IL-6, GP25, CRP indicate a certain relationship between them in the development of anemia with VDF in breast cancer patients and the need for further study of the characteristics of iron metabolism in cancer patients.
About the authorsBlindar Valentina Nikolaevna
Rodgers G.M., Becker P.S., Blinder M., Cella D., Chanan-Khan A, Cleeland C. et al. Cancer- and chemotherapy-induced anemia. Journal of the National Comprehensive Cancer Network. 2012; 10(5): 628–53.
Aapro M., Beguin Y., Bokemeyer C., Dicato M., Gascón P., Glaspy J. et al. Management of anemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Annals of Oncology. 2018; 29(4): 96–110. https://doi.org/10.1093/annonc/mdx758
World Medical Association, Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013; 310(20): 2191–4. PMID 24141714, https://doi.org/10.1001/jama.2013.281053
Ganz T., Nemeth E. Hepcidin and disorders of iron metabolism. Annual Review of Medicine. 2011; 62: 347–60.
Для цитирования: Блиндарь В.Н., Зубрихина Г.Н., Давыдова Т.В., Добровольская М.М., Хагажеева М.Н., Снеговой А.В., Любимова Н.В., Кушлинский Н.Е., Рябчиков Д.А. Оценка нарушений метаболизма железа и адекватности лечения анемического синдрома у больных раком молочной железы на фоне адъювантной химиотерапии. Клиническая лабораторная диагностика. 2022; 67(4): 213-218. https://doi.org/10.51620/0869-2084-2022-67-4-213-218
For citation: Blindar V.N., Zubrikhina G.N., Davydova T.V., Dobrovolskaya M.M., Khagazheeva M.N., Snegovoy A.V., Lyubimova N.V., Kushlinskii N.E., Ryabchikov D.A. Assessment of iron metabolism disorders and adequate treatment of anemic syndrome in patients with breast cancer on the background of adjuvant chemotherapy. Klinicheskaya laboratornaya diagnostika (Russian Clinical Laboratory Diagnostics). 2022; 67(4): 213-218 (in Russ.). https://doi.org/10.51620/0869-2084-2022-67-4-213-218
- Refbacks are not listed
Контент доступен под лицензией Creative Commons Attribution 3.0 License.